Milophene

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Milophene

Property Description
Active ingredient Clomifene Citrate
Form Oral Tablet
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
General purpose Ovulation Stimulation
Origin Synthetic, Non-steroidal

What Kind of Medicine is Milophene? (Definition and Classification)

Milophene is a prescription medication whose active ingredient is Clomifene Citrate, formally classified as a Selective Estrogen Receptor Modulator (SERM). This synthetic, non-steroidal compound is an Ovulation Stimulator that influences the reproductive hormone system. Clomifene Citrate is a fertility agent designed to address difficulties with natural ovulation by modulating estrogen signaling pathways in the central nervous system. This functionality facilitates indirect hormonal action to promote the physiological conditions necessary for fertility.

Composition and Form of Milophene Tablets

Milophene is administered orally and is provided in the physical form of a tablet. As a single active ingredient product, its composition is centered around Clomifene Citrate, a compound that is chemically a mixture of two geometric isomers, zuclomiphene and enclomiphene. This tablet structure, combined with standard pharmaceutical excipients, ensures the drug is delivered through the digestive system. Chemically, Clomifene belongs to the triphenylethylene derivatives.

What is the General Purpose of Clomifene Citrate?

The general purpose of Clomifene Citrate is to induce or restore regular ovulation by stimulating the body's natural reproductive control center. It accomplishes this by briefly blocking estrogen receptors in the hypothalamus, which causes the pituitary gland to increase the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This controlled hormonal cascade promotes the development of mature ovarian follicles and the subsequent release of an egg, characterizing the drug’s function as a pro-fertility agent for managing anovulatory infertility.

Regulatory References

  1. MedlinePlus: Clomiphene

What side effects are possible with Milophene?

Possible Side Effects and Safety Information

Milophene (clomiphene citrate) is associated with officially documented adverse reactions that primarily affect the reproductive, vascular, and nervous systems. The most commonly reported side effects include ovarian enlargement, vasomotor flushes (hot flashes), and abdominal/pelvic discomfort or bloating. Other frequent reactions are nausea, vomiting, breast discomfort, headache, and abnormal uterine bleeding.

System/Adverse Reaction Category Examples of Reported Reactions
Reproductive/Endocrine Ovarian enlargement, Ovarian Hyperstimulation Syndrome (OHSS), multiple pregnancy, risk of ovarian tumor (with prolonged use)
Visual/Nervous System Blurred vision, scotomata (seeing spots/flashes), photophobia, potentially prolonged or irreversible visual disturbances
Gastrointestinal Abdominal/pelvic discomfort, nausea, vomiting, pancreatitis (rare postmarketing)

Serious Safety Considerations and Restrictions

The most serious documented adverse event is Ovarian Hyperstimulation Syndrome (OHSS), which can be life-threatening and requires immediate medical attention. Visual symptoms may also occur and, particularly with increased dosage or duration, may be prolonged and potentially irreversible; these symptoms can impair activities like driving.

This medication is contraindicated during pregnancy due to the potential for fetal harm. It is also contraindicated in individuals with active liver disease or a history of liver dysfunction, abnormal uterine bleeding of undetermined origin, or ovarian cysts or enlargement not due to Polycystic Ovary Syndrome (PCOS).

Treatment is typically limited to a maximum of about six cycles, as long-term cyclic use has been associated with a potential increase in the risk of borderline or invasive ovarian tumors. Monitoring for ovarian enlargement via pelvic examination is necessary before and during each course of therapy.

Overdose and Emergency Response

Milophene Overdose and When to Seek Help

The official regulatory documentation for Milophene (Clomifene Citrate) defines specific clinical manifestations and mandated actions required in case of overexposure.

Documented Overdose Manifestations

Overdose or excessive response has been associated with acute physiological changes, including visual disturbances (such as scotomata, spots, flashes, and blurring), nausea, vomiting, vasomotor flushes (hot flashes), and ovarian enlargement accompanied by pelvic or abdominal pain. Regulatory warnings note that the incidence of visual symptoms increases with the overall total dosage or duration of use.

Serious Outcome and Emergency Response

A critical concern associated with overexposure is the potential development of Ovarian Hyperstimulation Syndrome (OHSS). This condition may rapidly progress to a severe or life-threatening medical disorder, involving serious complications such as pulmonary oedema, acute respiratory distress, or renal failure.

Required Action: Individuals must immediately seek emergency medical attention or contact a Poison Help line if overdose is suspected or if symptoms of severe OHSS develop.

Management and Treatment

No specific antidote is known for Clomifene Citrate overdosage. The officially documented approach to management is therefore limited to symptomatic and supportive measures, which may include procedures like gastrointestinal decontamination or gastric lavage, as described in regulatory prescribing information.

Therapeutic Uses of Milophene

What Milophene Treats: Main Uses and Benefits

Milophene, known generically as Clomiphene Citrate, is applicable within clinical settings that involve acute or disruptive symptom patterns linked to reproductive challenges. It is commonly used when short-term symptomatic assistance is needed to address systemic imbalance. Usage includes situations where patients experience symptomatic discomfort related to irregular ovulation.


Management of Systemic Imbalance in Reproductive Health

Milophene is commonly used to help manage conditions characterized by periods of heightened symptoms related to reproductive fluctuations, such as in situations involving Polycystic Ovary Syndrome (PCOS). It is considered relevant when supportive symptom management is appropriate, as it supports patients during episodes of heightened discomfort and assists with maintaining functional stability.


Providing Supportive Assistance for Episodic Changes and Functional Strain

The medication is applied during phases where the patient experiences heightened discomfort or functional strain linked to systemic or organ-specific stress. It is relevant in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that assists with maintaining a sense of stability when symptoms become more noticeable. This helps ease the overall symptom load associated with these fluctuations.

Quick Fact: Support for Symptom Management
Milophene provides support that helps ease the overall symptom load associated with conditions where symptoms may intensify temporarily, assisting with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Clomiphene

Eligibility and Restrictions for Use

Eligibility Scope

Milophene (Clomifene Citrate) is strictly indicated for adult women with demonstrated ovulatory dysfunction who are attempting pregnancy. Official regulatory documents define absolute prohibitions and populations for whom use is not recommended.


Eligibility Status Populations as per Official Labeling
Absolutely Contraindicated Pregnancy; Patients with liver disease or a history of liver dysfunction; Abnormal uterine bleeding of undetermined origin; Ovarian cysts or enlargement not due to Polycystic Ovary Syndrome (PCOS); Uncontrolled thyroid or adrenal dysfunction; or an organic intracranial lesion such as a pituitary tumor.
Not Recommended Children and adolescents (pediatric use); Post-menopausal women (due to lack of therapeutic benefit).
Caution Exercised Patients with uterine fibroids (due to potential for enlargement); Breastfeeding women (as Clomifene may suppress lactation); Patients with pre-existing or family history of hypertriglyceridemia (requires monitoring).

The regulatory profile ensures the medicine is confined to its narrow target population by formally prohibiting use in patients with specific health conditions, physiological states, and non-target age groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official government regulatory documents for Milophene (Clomifene Citrate) do not generally detail comprehensive lists of specific drug-drug, metabolic, or transporter-based interactions that would necessitate mandatory dosage changes or timing separation with co-administered medicinal products.


Absence of Documented Pharmacokinetic Interactions

The regulatory profile is structured by the absence of explicit documentation regarding how co-administered agents affect Clomifene Citrate's plasma exposure, and vice versa. Official labeling does not define specific interaction patterns related to drug metabolism via cytochrome P450 (CYP) enzymes or formal pharmacodynamic (PD) interactions.

Interaction Category Regulatory Status
Drug-Drug Combinations No specific combinations are formally prohibited due to interaction risk.
Food, Alcohol, Supplements No specific warnings or restrictions are listed in regulatory documents.

Population-Specific Interaction Consideration

The only specific interaction-related caution documented in official labeling concerns a defined patient risk factor: hypertriglyceridemia. Cases of elevated plasma triglycerides have been reported, and the risk is higher in patients with a preexisting or family history of hyperlipidemia. This necessitates periodic monitoring of plasma lipids in at-risk individuals, which is an interaction-context constraint tied to the patient's existing condition rather than a co-administered substance.

Mechanism of Action

Serotonin Reuptake Inhibition and Synaptic Action

Milophene's primary molecular action is as a Selective Inhibitor of the Serotonin Transporter (SERT), a protein located on the presynaptic neuronal membrane. By binding to SERT, the drug prevents the active reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft. This blockade leads to an immediate increase in the concentration and duration of serotonin exposure on postsynaptic receptors, initiating the downstream molecular cascade.

Adaptive Neural Signaling and Regulation

Milophene's action primarily engages central nervous system (CNS) pathways, altering signaling dynamics within systems like the Raphe nuclei projection systems. The sustained increase in synaptic serotonin triggers a necessary secondary physiological process: the gradual downregulation and desensitization of certain postsynaptic receptor populations. This mechanism modifies pathways involved in serotonergic signaling and neuroplasticity, resulting in adaptive changes to postsynaptic receptor expression that emerge over a period of weeks.

Dosage and Administration Information

How Milophene is used

Milophene, which contains the active ingredient Clomifene Citrate, is administered via the oral route as a 50 mg tablet. The use of this medicine is structured around a cyclic regimen and is performed under the supervision of physicians experienced in managing gynecologic disorders.

The standard administration protocol specifies a course length of five consecutive days. Treatment typically begins with an initial dose of 50 mg once daily for this 5-day period. For patients who do not ovulate in response to the initial course, the dosing schedule allows for an increase to a second course of 100 mg once daily for 5 days. The protocol indicates that the dosage or duration is not to exceed 100 mg per day for five days in any single course.

In patients who experience spontaneous or progestin-induced uterine bleeding, the 5-day course is conventionally started on or about the 5th day of the menstrual cycle. The treatment protocol requires a minimum interval of approximately 30 days between courses. Procedurally, a pelvic examination is conducted prior to the initiation of the first course and before each subsequent course of treatment. Long-term cyclic therapy is generally limited to a total of approximately six cycles, and use requires the presence of normal liver function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Milophene

Evidence for Use in Anovulatory Infertility

Research has focused on Milophene, known generically as Clomifene Citrate, in women experiencing anovulatory or oligo-ovulatory infertility—meaning they rarely or never ovulate on their own. The medicine was evaluated in research settings involving anovulatory infertility, which is a condition marked by functional limitations related to the menstrual cycle. The majority of the formal evidence comes from Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that synthesize the data from these trials.

In these research scenarios, investigators explored whether Milophene was associated with changes in two main outcomes related to physiological strain or stress: the ovulation rate and the Live Birth Rate. Studies primarily monitored adult women of reproductive age who had this ovulatory challenge, including a large focus on patients whose anovulation was associated with Polycystic Ovary Syndrome (PCOS). Studies monitored physiological strain or stress by reporting patterns observed regarding the ovulation response in the studied populations.


Study Design and Comparison Trials

Milophene was evaluated in settings comparing it to a placebo or to no treatment at all. Additionally, numerous studies explored how Milophene was associated with outcomes when compared against other pharmaceutical agents or when used in combination with other treatments. These comparison trials describe patterns observed in the studies regarding outcomes related to physiological strain or stress and the measured clinical outcomes, such as pregnancy or live birth rates, within the study intervals.


What is Still Uncertain About Milophene's Research

The research on Milophene, while extensive, highlights several areas where certainty remains low or where additional research is needed. A central issue is the inconsistent findings and the documented difference where ovulation rate (a biological measure) often appears to be higher than the corresponding live Birth Rate reported in studies. Additionally, evidence quality varies across studies, particularly older ones, where sample sizes were limited and methodologies were sometimes heterogeneous.

Frequently Asked Questions (FAQ)

Common questions about Milophene (FAQ)


Q: How quickly does Milophene usually start working for people?

A: Milophene works by stimulating the release of key reproductive hormones in the body. Based on the medication's intended clinical effect, ovulation is observed to occur in studied populations generally within 5 to 10 days after the completion of a 5-day course.

Q: How long does the effect of one Milophene dose last?

A: Official information indicates that Milophene's active components have varying durations in the body. Because one of the drug's isomers (a type of chemical structure) has a significantly long half-life, trace amounts of the drug's components may be detected in the system for up to six weeks following the treatment course.

Q: Does taking Milophene make you feel tired or energized?

A: While tiredness or fatigue is not listed among the most commonly reported adverse effects, it has been noted in post-marketing reports from users. Changes in energy levels, if experienced, should be discussed with a healthcare provider.

Q: Is Milophene similar to other drugs like [Name of Similar Drug]?

A: Regulatory documents classify Milophene (Clomifene Citrate) as a Selective Estrogen Receptor Modulator (SERM). This classification describes the drug’s primary function in influencing estrogen signaling pathways.

Q: How is Milophene typically eliminated from the body?

A: According to the official product information, Milophene is processed by the body and primarily eliminated through the feces. A small amount of the drug is also excreted through the urine.

Q: Is there a generic version of Milophene available?

A: Yes, the FDA has approved generic versions of the active ingredient, which is known as Clomiphene Citrate. These generic forms are available from multiple different manufacturers.

Q: What does 'contraindication' mean in the context of Milophene?

A: A contraindication refers to a specific condition or factor that officially prohibits the use of Milophene because it could be inappropriate or potentially harmful. Specific conditions listed as contraindications in the official documentation include pregnancy and active liver disease.

Q: What is the official safety classification of Milophene?

A: Milophene is strictly contraindicated in pregnancy due to the potential for fetal harm. Due to the potential for harm to the fetus, the drug has been classified by regulatory bodies as Pregnancy Category X.

Q: Does Milophene carry any specific warnings for individuals with heart conditions?

A: While there is no universal, specific contraindication for pre-existing heart conditions listed in all regulatory documents, the drug's official profile notes that post-marketing reports have included the occurrence of cardiovascular events, such as chest pain, hypertension (high blood pressure), and irregular heartbeats.

Q: Does Milophene cause weight gain or loss?

A: Weight changes are not listed among the most frequently reported side effects. However, both weight gain and weight loss have been noted in post-marketing experience from users.

Q: Does Milophene affect sleep patterns?

A: Official adverse reaction reports include instances of trouble sleeping, also known as insomnia. This is generally reported in the category of less common or rare side effects.

Q: What should I do if I think I missed a dose of Milophene?

A: Official documentation stipulates that individuals should contact a doctor or pharmacist for specific instructions regarding a missed dose. It is also noted that a double dose should not be taken to make up for the one that was missed.

Q: How long does it take for Milophene to be fully cleared from the system after the last dose?

A: Due to the long half-life of one of the drug's chemical structures (isomers), detectable amounts of the medicine may remain present in the body for an extended period. This clearance time can be as long as six weeks after the final dose is administered.

Q: What is the purpose of the inactive ingredients in the Milophene tablet?

A: The official product description lists several inactive ingredients, or excipients, such as lactose and corn starch. These components do not have a medical effect but are used to form the physical tablet and ensure the medication remains stable and is properly delivered to the body.

Q: How does the time of day I take Milophene matter?

A: While specific medical instruction regarding the time of day is not universally present, regulatory guidance notes that taking the medicine at the same time every day may support adherence to the prescribed treatment schedule.

Q: What are the signs of taking too much Milophene, according to official warnings?

A: Signs of taking too much Milophene (overdosage) noted in the official product information include nausea and vomiting, vasomotor flushing (hot flashes), severe pelvic pain due to ovarian enlargement, and various visual disturbances such as blurring, seeing spots, or flashes.

Q: Are there any known severe allergic reactions associated with Milophene?

A: Allergic reactions have been documented in post-marketing experience. Reported signs may include skin rash, itching, hives, and swelling.

Q: Can Milophene cause changes in mood or behavior?

A: Official reports indicate that psychiatric side effects have been reported. Reported events have included anxiety, irritability, changes in mood, and, in some rare instances, psychosis.

Q: Are there any long-term effects of Milophene that studies are still following?

A: One long-term concern noted on the regulatory label is the potential risk of developing borderline or invasive ovarian tumors associated with prolonged cyclic use, typically beyond the recommended maximum course of therapy.

Q: What are the less common, but officially listed, side effects of Milophene?

A: Less common side effects noted in official documentation include dizziness, nervousness, blurred vision, and mental depression, among others.

How should Milophene be stored and disposed of?

How to Store and Dispose of Milophene

Milophene (clomiphene citrate) tablets must be stored according to regulatory labeling to maintain product stability.

Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F).
Protection Store away from heat, light, and excessive moisture. The medication must be kept from freezing.
Child Safety The product must be kept out of the reach of children.

Disposal of Unused Medicine

To dispose of unused or expired Milophene, the official guidance directs the use of a drug take-back program where available. If no take-back program exists, the tablets should be mixed with an undesirable substance, such as dirt or used coffee grounds, sealed in a bag, and then placed in the household trash. The empty prescription container must have all personal information removed before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Milophene found in:

A-Z Index: